Get the Stockscreener App
1.44
4.35%
0.06
After Hours:
1.45
0.01
+0.69%
Aclaris Therapeutics Inc Stock (ACRS) Forecast
The Aclaris Therapeutics Inc (ACRS) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $2.7468, representing a +90.75% increase from the current price of $1.44. The highest analyst price target is $2.7018, and the lowest is $2.7918.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ACRS Price Target
Average 11.99
(+732.34% Upside)
Is Aclaris Therapeutics Inc (ACRS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 55.52 | Neutral |
| STOCH(9,6) | 79.47 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | -0.0465 | Buy |
| ADX(14) | 27.48 | Buy |
| William %R | -12.20 | Sell |
| CCI(14) | 78.23 | Neutral |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.292
Buy
|
1.3275
Buy
|
| MA20 |
1.2445
Buy
|
1.3315
Buy
|
| MA50 |
1.5366
Sell
|
1.5576
Sell
|
| MA100 |
2.1014
Sell
|
1.7989
Sell
|
| MA200 |
1.907
Sell
|
1.822
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, ACRS could be considered a Moderate Sell, with 17 technical analysis indicators signaling 6 Buy signals, 8 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on ACRS, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 55.52 indicates that ACRS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 79.47 indicates that ACRS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that ACRS is oversold. This suggests that ACRS price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 27.48 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 78.23 indicates that ACRS is still overbought but not to an extreme extent.
Long-term ACRS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Aclaris Therapeutics Inc financial reports and earnings history, Aclaris Therapeutics Inc (ACRS) stock could reach $4.4985 by 2030, $4.2578 by 2040 and $3.876 by 2050. See the projected annual prices until 2050 of the Aclaris Therapeutics Inc stock below:
- Aclaris Therapeutics Inc (ACRS) is expected to reach an average price of $1.8612 in 2035, with a high prediction of $2.9542 and a low estimate of $1.5485. This indicates an $29.25% rise from the last recorded price of $1.44.
- Aclaris Therapeutics Inc (ACRS) stock is projected to chart a bullish course in 2040, with an average price target of $3.5458, representing an $146.24% surge from its current level. The forecast ranges from a conservative $2.5616 to a sky-high $4.2578.
- Our analysts predict Aclaris Therapeutics Inc (ACRS) to jump 387.47% by 2045, soaring from $3.9231 to an average price of $7.0196, potentially reaching $8.9274. While $3.9231 is the low estimate, the potential upside is significant.
- Aclaris Therapeutics Inc (ACRS) stock is expected to climb by 2050, reaching an average of $3.796, a $163.61% jump from its current level. However, a wide range of estimates exists, with high and low targets of $3.876 and $1.0457, respectively, highlighting the market's uncertainty.
Aclaris Therapeutics Inc Stock (ACRS) Year by Year Forecast
Aclaris Therapeutics Inc Stock (ACRS) Price Forecast for 2025
Aclaris Therapeutics Inc Stock (ACRS) is expected to reach an average price of $1.5786 in 2025, with a high prediction of $3.1333 and a low estimate of $0.0238. This indicates an +9.62% rise from the last recorded price of $1.44.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| June, 2025 | $2.6864 | $2.7918 | $2.7018 | +86.56% |
| July, 2025 | $2.293 | $2.5707 | $2.6037 | +59.23% |
| August, 2025 | $1.8822 | $2.3322 | $2.2376 | +30.71% |
| September, 2025 | $1.7115 | $1.7568 | $1.6295 | +18.85% |
| October, 2025 | $1.608 | $1.3307 | $1.253 | +11.67% |
| November, 2025 | $1.1273 | $1.2673 | $1.4553 | -21.72% |
| December, 2025 | $0.2062 | $0.0238 | $1.3681 | -85.68% |
Aclaris Therapeutics Inc Stock (ACRS) Price Forecast for 2026
The predicted value for Aclaris Therapeutics Inc (ACRS) in 2026 is set at an average of $13.54. Estimates vary from a peak of $27.06 to a trough of $0.0189, indicating an +840.18% surge from the present price of $1.44.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.2631 | $0.0189 | $0.6089 | -81.73% |
| February, 2026 | $1.9877 | $0.075 | $3.1577 | +38.03% |
| March, 2026 | $2.3984 | $1.8104 | $4.443 | +66.56% |
| April, 2026 | $17.78 | $9.8211 | $22.05 | +1,135% |
| May, 2026 | $23.42 | $16.10 | $23.95 | +1,527% |
| June, 2026 | $25.64 | $18.22 | $27.06 | +1,681% |
| July, 2026 | $17.94 | $17.43 | $25.48 | +1,146% |
| August, 2026 | $15.18 | $13.62 | $20.80 | +954.00% |
| September, 2026 | $14.45 | $13.26 | $15.70 | +903.54% |
| October, 2026 | $11.82 | $10.63 | $14.80 | +720.61% |
| November, 2026 | $13.17 | $9.7471 | $13.24 | +814.76% |
| December, 2026 | $14.96 | $13.03 | $17.00 | +938.61% |
Aclaris Therapeutics Inc Stock (ACRS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Aclaris Therapeutics Inc (ACRS) is $11.40, with a high forecast of $16.28 and a low forecast of $6.527. This indicates an +691.76% increase from the last price of $1.44.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $13.43 | $12.71 | $15.80 | +832.41% |
| February, 2027 | $10.92 | $10.38 | $15.72 | +658.16% |
| March, 2027 | $11.17 | $9.0782 | $11.61 | +675.76% |
| April, 2027 | $8.0516 | $7.6616 | $12.76 | +459.14% |
| May, 2027 | $8.5224 | $6.527 | $9.1224 | +491.83% |
| June, 2027 | $13.17 | $8.4251 | $13.24 | +814.29% |
| July, 2027 | $14.65 | $11.54 | $16.00 | +917.12% |
| August, 2027 | $12.56 | $12.27 | $15.10 | +772.04% |
| September, 2027 | $10.52 | $7.3354 | $12.84 | +630.61% |
| October, 2027 | $13.18 | $10.00 | $13.48 | +815.38% |
| November, 2027 | $13.96 | $10.85 | $14.48 | +869.60% |
| December, 2027 | $14.49 | $11.10 | $16.28 | +905.95% |
Aclaris Therapeutics Inc Stock (ACRS) Price Forecast for 2028
In 2028, Aclaris Therapeutics Inc (ACRS) is projected to reach an average price of $10.37, with a high projection of $16.85 and a low estimate of $3.8998. This indicates an +620.38% rise from the last price of $1.44.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $14.86 | $13.38 | $15.96 | +931.70% |
| February, 2028 | $13.53 | $10.60 | $15.64 | +839.39% |
| March, 2028 | $13.46 | $12.00 | $15.14 | +834.77% |
| April, 2028 | $15.43 | $12.76 | $16.85 | +971.63% |
| May, 2028 | $13.04 | $11.98 | $15.59 | +805.89% |
| June, 2028 | $14.67 | $12.64 | $16.48 | +918.44% |
| July, 2028 | $12.36 | $11.48 | $16.58 | +758.08% |
| August, 2028 | $6.0198 | $3.8998 | $12.61 | +318.04% |
| September, 2028 | $7.3005 | $5.8152 | $7.3705 | +406.98% |
| October, 2028 | $7.2113 | $6.7386 | $7.8459 | +400.78% |
| November, 2028 | $7.0847 | $6.124 | $7.4147 | +392.00% |
| December, 2028 | $8.7155 | $6.8524 | $9.2428 | +505.24% |
Aclaris Therapeutics Inc Stock (ACRS) Price Forecast for 2029
The 2029 price forecast for Aclaris Therapeutics Inc Stock (ACRS) is $4.7523 on average, with a high prediction of $9.5036 and a low estimate of $0.00107. This represents an +230.02% increase from the previous price of $1.44.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $8.2789 | $7.9762 | $9.5036 | +474.93% |
| February, 2029 | $5.3597 | $5.2397 | $8.5716 | +272.20% |
| March, 2029 | $6.0604 | $4.9924 | $6.7854 | +320.86% |
| April, 2029 | $3.8812 | $3.7412 | $6.0631 | +169.53% |
| May, 2029 | $3.3796 | $2.9166 | $4.3296 | +134.70% |
| June, 2029 | $0.421 | $0.4846 | $0.3962 | -70.76% |
| July, 2029 | $0.2239 | $0.2439 | $0.2066 | -84.45% |
| August, 2029 | $0.0504 | $0.0504 | $0.0969 | -96.50% |
| September, 2029 | $0.0303 | $0.0174 | $0.1053 | -97.89% |
| October, 2029 | $0.0538 | $0.00107 | $0.3884 | -96.27% |
| November, 2029 | $0.1945 | $0.0664 | $0.2545 | -86.49% |
| December, 2029 | $3.465 | $0.1072 | $2.51 | +140.63% |
Aclaris Therapeutics Inc Stock (ACRS) Price Forecast for 2030
Aclaris Therapeutics Inc Stock (ACRS) is expected to reach an average price of $6.002 in 2030, with a high forecast of $8.1194 and a low forecast of $3.8846. This signifies an +316.81% surge from the last price of $1.44.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $4.6331 | $3.8846 | $4.4985 | +221.74% |
| February, 2030 | $7.0416 | $4.8077 | $6.7716 | +389.00% |
| March, 2030 | $8.01 | $7.2097 | $7.8401 | +456.25% |
| April, 2030 | $8.0086 | $8.0686 | $8.1194 | +456.15% |
| May, 2030 | $7.8217 | $7.7671 | $7.9332 | +443.18% |
| June, 2030 | $6.9929 | $7.3802 | $7.7164 | +385.62% |
| July, 2030 | $6.9983 | $6.9495 | $6.8194 | +386.00% |
| August, 2030 | $6.6018 | $6.8118 | $6.898 | +358.46% |
| September, 2030 | $6.3103 | $6.6811 | $6.5557 | +338.22% |
| October, 2030 | $6.9735 | $6.625 | $6.8988 | +384.27% |
| November, 2030 | $7.3118 | $7.0281 | $7.14 | +407.76% |
| December, 2030 | $7.0355 | $7.1558 | $7.2366 | +388.57% |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):